Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …

Apremilast is the first small molecule approved for the treatment of moderate to severe
psoriasis and psoriatic arthritis in adult patients. To evaluate survival, efficacy and safety of …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Psoriasis is a chronic, inflammatory, immune‐mediated disease of the skin and joints.
Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Introduction: Apremilast is an oral phosphodiesterase inhibitor, approved for moderate to
severe psoriasis in adults. Despite the advancement in dermatology, and the introduction of …